Aitia’s CEO Wants You to Use AI to Do More than Designing Drugs Against Known Validated Targets
AI in the pharma R&D world isn’t just about designing better drugs against known drug targets, according to Aitia’s CEO, Colin Hill. Hear what Colin had to say on how powerful AI can be in understanding novel human causal biology, creating novel drugs, and enhancing patient selection in clinical trials. Full article on DPHARM, here. […]
Digital Twins: When AI drives progress for the pharmaceutical industry
In its inaugural edition, Servier digital magazine, Insights, features Aitia’s Gemini Digital Twins in its “Science Calling” section. The conversion of causal AI and Gemini Digital Twins with industrial expertise holds the potential to significantly expedite R&D phases and streamline the identification of new targets. In May 2023, Aitia and Servier inked a multi-year agreement […]
How Digital Twins are Transforming Medicine
What if you could test a drug candidate on people before clinical trials? What if, instead of mice, a human computer model could be the first “lab rat” to determine the efficacy of a molecule, or to provide insight into a potential drug target? Hear from our CEO, Colin Hill, as he unveils the transformative […]
HDTC Poster | Prediction of HD-related clinical outcome progression and imaging markers using AI-based Digital Twins
Pahriya Ashrap, So-Youn Shin, Jeanne Latourelle
Causal AI to learn “Gemini Digital Twins” for Drug Discovery and Clinical Development: Join our CMO, Bruce Church at AIRIS 2024
We are excited to announce that Aitia will be participating at the AI Regulatory & International Symposium 2024 conference in Seoul, Korea. Our Chief Mathematics Officer, Bruce Church, will be taking the stage in the New Medical Products and Treatment Opportunities Using AI session to talk about Aitia’s commitment in accelerating AI-driven discoveries and share […]
Meet us at WSJ Health Forum
Join our CEO, Colin Hill with an influential community of scientists, business leaders, investors, policymakers and experts from across the sector to explore the trends, technologies, ideas and opportunities reshaping the business and science of health on Feb 21, 2024 in Boston at WSJ Forum. Find more details here.
Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights
JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]
Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug
Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease. Read the full article on […]
Meet us at J.P.Morgan Healthcare Conference
As we prepare to wrap up another exciting year for Aitia, we’re eagerly looking forward to a bustling 2024. For now, we’re gearing up for the J.P. Morgan conference, where our CEO, Colin Hill and President, COO, Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the […]
Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]